Who owns VISTAGEN THERAPEUTICS ORD?
- Ticker: VTGN
- CUSIP Number: 92840h400
Tip: Access positions for across all investors
Analyze quarterly positions in Vistagen Therapeutics Ord with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Vistagen Therapeutics Ord stock
Who bought or sold VISTAGEN THERAPEUTICS ORD this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| BVF | 2.0M | $11M | 0% | Mar 2024 |
|
| Dr. Jeffrey R. Jay, M.D. | 1.9M | $9.8M | 0% | Mar 2024 |
|
| Vanguard Group | 1.8M | $9.5M | -2% | Mar 2024 |
|
| Commodore Capital | 1.6M | $8.3M | 0% | Mar 2024 |
|
| Nantahala Capital Management | 1.5M | $8.0M | -16% | Mar 2024 |
|
| Citadel Advisors | 821k | $4.3M | 0% | Mar 2024 |
|
| Sphera Funds Management | 809k | $4.3M | 0% | Mar 2024 |
|
| Susquehanna International | 586k | $3.1M | 17% | Mar 2024 |
|
| Armistice Capital | 364k | $1.9M | 100% | Mar 2024 |
|
| BlackRock | 348k | $1.8M | 296% | Mar 2024 |
|
| Geode Capital Management | 280k | $1.5M | 282% | Mar 2024 |
|
| Goldman Sachs Group | 166k | $877k | 1% | Mar 2024 |
|
| BML Capital Management | 150k | $792k | 0% | Mar 2024 |
|
| Two Sigma Investments | 144k | $762k | -25% | Mar 2024 |
|
| ADAR1 Capital Management | 90k | $475k | -63% | Mar 2024 |
|
| AdvisorShares Investments | 72k | $381k | 100% | Mar 2024 |
|
| William Blair $ Company | 69k | $362k | -22% | Mar 2024 |
|
| Northern Trust | 50k | $264k | 244% | Mar 2024 |
|
| Millennium Management | 37k | $193k | 100% | Mar 2024 |
|
| Citigroup | 35k | $185k | -40% | Mar 2024 |
|
| Acadian Asset Management | 32k | $169k | 100% | Mar 2024 |
|
| Charles Schwab Investment Management | 23k | $123k | 0% | Mar 2024 |
|
| Barclays | 23k | $122k | 0% | Mar 2024 |
|
| Morgan Stanley | 22k | $113k | 738% | Mar 2024 |
|
| American Century Companies | 20k | $107k | 100% | Mar 2024 |
|
| ExodusPoint Capital Management | 18k | $97k | 100% | Mar 2024 |
|
| Advisor Group Holdings | 12k | $62k | 11% | Mar 2024 |
|
| Bank of America Corporation | 10k | $51k | -48% | Mar 2024 |
|
| GPS Wealth Strategies Group | 8.4k | $45k | 0% | Mar 2024 |
|
| UBS Group | 4.7k | $25k | 3948% | Mar 2024 |
|
| Tower Research Capital | 3.4k | $18k | 100% | Mar 2024 |
|
| CWM | 2.4k | $13k | -1% | Mar 2024 |
|
| BFSG | 1.0k | $5.3k | 0% | Mar 2024 |
|
| Wells Fargo & Company | 211.00 | $1.1k | 1% | Mar 2024 |
|
| EverSource Wealth Advisors | 88.00 | $452.003200 | 0% | Mar 2024 |
|
| Farther Finance Advisors | 81.00 | $437.003100 | 100% | Mar 2024 |
|
| Fairman Group | 29.00 | $153.001100 | 0% | Mar 2024 |
|
| Jpmorgan Chase & Co | 16.00 | $84.000000 | 0% | Mar 2024 |
|
Who sold out of Vistagen Therapeutics Ord?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Bank Of Montreal | Dec 2023 | 97k | $524k |
| Gts Securities | Dec 2023 | 85k | $439k |
| Group One Trading | Sep 2023 | 75k | $395k |
| Boothbay Fund Management | Sep 2023 | 47k | $246k |
| DAFNA Capital Management | Dec 2023 | 42k | $215k |
| Jane Street | Dec 2023 | 22k | $113k |
| Springbok Capital Management | Sep 2023 | 20k | $106k |
| Virtu Financial | Dec 2023 | 16k | $80k |
| Bank of New York Mellon | Dec 2023 | 15k | $78k |
| Simplex Trading | Dec 2023 | 12k | $63k |
| Janney Montgomery Scott | Dec 2023 | 10k | $51k |
| Royal Bank of Canada | Dec 2023 | 1.4k | $7.0k |
| Qube Research & Technologies | Sep 2023 | 1.2k | $6.2k |
| Cutler | Dec 2023 | 200.00 | $1.0k |